filmov
tv
#ESMO21 Highlights on gemcitabine vs mFOLFIRINOX in resected pancreatic cancer: PRODIGE 24/CCTG PA6
Показать описание
Thierry Conroy reports on key results from ESMO Congress 2021 on LBA57 - Unicancer GI PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter randomized phase 3 trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas.
Produced by the European Society for Medical Oncology
Produced by the European Society for Medical Oncology
0:02:30
0:03:18
0:02:45
0:02:51
0:02:47
0:02:59
0:01:35
0:02:26
0:02:19
0:03:27
0:02:42
0:02:18
0:03:40
0:01:38
0:03:49
0:06:03
0:01:46
0:03:39
0:02:34
0:01:00
0:04:03
0:01:19
0:01:06
0:01:41